AzTrials
AzTrials

SarcopeniaNCT02890290

Effect Study of Marine Protein Hydrolysates to Prevent Loss of Muscle Mass and Physical Function in Frail Elderly

A study testing Marine Protein hydrolysate in people with Sarcopenia, run by Molde University College.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The purpose of this study is to determine whether a marine protein hydrolysate given as a supplement can prevent age related loss of muscle mass and loss of physical function in frail elderly. Read more about this study

Who is it for?
Ages 65 years and older
Conditions the study is for
Sarcopenia
What is being tested?
Marine Protein hydrolysate
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
92 participants
Where
No sites listed yet
Study dates
Sep 2016to Jul 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 65 years and older
  • All sexes
  • No healthy volunteers
  • Older adult

Who may be able to join

  • able and willing to give consent
  • Must be able to swallow tablets

Who cannot join

  • diabetes (recieve treatment)
  • active cancer illness
  • progressive muscle illness (e.g. multiple sclerosis ALS)
  • kidney failure
  • short life expectancy (<1år)
  • allergies of fish protein.

About this study

Official title: Nutrition and Sarcopenia in Frail Elderly: a Randomized Controlled Trial of the Effects of Marine Protein Hydrolysates to Improve Physical Performance.

The purpose of this study is to determine whether a marine protein hydrolysate given as a supplement can prevent age related loss of muscle mass and loss of physical function in frail elderly. The study will recruit elderly living at home with help from municipal health care services, and a secondary goal of the study is to describe food habits, seafood intake and nutritional status in this group of patients.

Edit: the recruitment procedure was changed in august 2017, to include elderly without help from municipal health care services. Participants are now recruited trough media and organizations for elderly, and these changes in recruitment procedure was approved by the ethics committee august 2017.

Read the detailed description

The overall objective in this project is to study how nutrition influences frailty and physical function in home-dwelling elderly.

The study will seek to answer the following hypotheses (RCT):

  1. Sarcopenia as measures by SPPB, grip strength, antropometry and gait speed is significantly associated with nutritional status and intake of protein in frail elderly.
  2. A supplement of 3000mg of marine peptides pr. day in 12 months in the intervention group will improve the score on SPPB and other sarcopenia-related outcomes like grip strength, antropometric measures or gait speed compared to the placebo group.

To supplement the results of the RCT, interviews will be performed with selected participants to answer the following question:

  • How do frail elderly describe their own nutritional status and need of help from municipal health care service related to nutrition? The data collection will be made in the participants' home at baseline and after 6 and 12 months. The patients will complete the Short Physical Performance Test (SPPB), Grip Strength measurement and anthropometric measurements (weight, height, calf circumference and mid-arm circumference). Assessment of nutritional status will be made by Mini Nutritional Assessment (MNA). Seafood intake and protein intake will be assessed by a food frequency questionnaire based on previously used and validated questionnaires. Daily energy intake will be estimated by a 24-hour multiple pass recall of food intake. Health related quality of life will be assessed by the EQ-5D-5L questionnaire (EuroQol). In addition, the participants will be asked to take blood tests to be analyzed for vitamin D, nutritional and inflammation markers.

Sample size and statistical power calculation The main outcome of this study is physical performance, measured on a 12 point ordinal scale; the SPPB. In accordance to previous studies, a clinical meaningful change in score on this scale is 0,4 - 1,5 points. Based on mean values and SD from the mentioned study, power was computed with SPSS (IMB) Power Sample for t-test of independent samples. The criterion for significance (alpha) has been set at 0,050 and the test is 2-tailed. With a sample size of 39 in each of the two groups, the study will have a power of 80% to yield a statistically significant result. This computation assumes a difference between groups of 0.9 points. As the participants are frail and of old age, we expect a dropout/missing frequency of 20 %, thus we should have 50 participants in each group.

Statistical analyzes The null hypothesis is that there is no difference between intervention and control group, in change of physical performance across multiple test attempts. Linear mixed model will be used to detect differences in treatments across multiple test attempts. Linear mixed model and ordinal regression models will be used to explore the relationship between nutrition and physical performance at baseline.

In-depth interviews Interviews will provide a deeper understanding of potential results in the RCT. Fifteen to twenty participants will be selected to the interviews by purposeful recruitment, based on results from the RCT study. The interviews will be transcribed and analyzed using qualitative content analysis.

Ethical consideration This project was approved by the Regional Committee in Ethics in Medical Research in Mid- Norway. The investigators do not anticipate this project causing any harm or discomfort to the participants, and will make sure that our participants participate in the study voluntarily. Participants will be given both oral and written information about the study twice before they give their consent to participate. First, they will receive information from their home care nurse, and if they agree to receive a call or visit from the researcher, they will have the opportunity to ask questions before signing the written consent. Participants not receiving municipal health care services sign their consent at the first visit. Furthermore, they will be informed about the possibility to withdraw from the study without any consequences at any time.

The project will have considerable benefits for this patient group. Increased knowledge of the nutritional status and protein intake in the patient group may facilitate nutritional interventions to prevent loss of physical function, potentially leading to increased independence and delayed need of residential institution. Results from the RCT may be transferable to other patient conditions where muscle atrophy is expected, e.g. inactivity after injuries, bed rest after surgery, or in intensive care units.

Conditions
Sarcopenia
Being tested
Marine Protein hydrolysate, Placebo
Keywords
Frail Elderly, Diet, Food, and Nutrition, physical function, marine protein hydrolysates, protein intake, seafood intake, ageing, old, nutrition, frail
Medical subject headings
Sarcopenia

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Marine Protein hydrolysateDietary supplement

    The participants will take the supplement in form of tablets and will be instructed to take five tablets twice a day, preferably in relation to meals, however, not the dinner meal. Each tablet contains 300 mg of marine protein hydrolysates (Nx6.25). The tablets are produced by Flexipharma AS.

  • PlaceboDietary supplement

    Placebo tablets will be made based on gum arabicum. The tablets are produced by Flexipharma AS.

Study groups in NCT02890290
Study groupRoleWhat they receive
InterventionActive comparatorMarine protein hydrolysate pills (3000mg)
Receives: Dietary Supplement: Marine Protein hydrolysate
ControlPlacebo comparatorPlacebo pills (gum arabicum)
Receives: Dietary Supplement: Placebo

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Short Physical Performance Battery (SPPB)

    physical test assessing balance, lower limb function and gait speed.

    Measured: 6 and 12 months

Secondary outcomes (4)
  1. Grip strength

    Measured in kg with dynamometer

    Measured: 6 and 12 months

  2. Gait speed

    m/s calculated from 4 meter walking test in SPPB

    Measured: 6 and 12 months

  3. Health related quality of life

    as measured by EQ-5D-5L

    Measured: 6 and 12 months

  4. Antropometric measures

    see protocol

    Measured: 6 and 12 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Sep 2016 (estimated)
  2. Study startSep 2016
  3. Primary completionJul 2019
  4. Study completionJul 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Prevention
Allocation
Randomised
Intervention model
Parallel groups
Masking
Quadruple blind
Who is masked
Participant, Care provider, Investigator, Outcomes assessor
Enrolment
92 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02890290
Sponsor's protocol ID
Nygard8362
Status last verified
Aug 2019
First submitted
31 Aug 2016
Last updated
28 Aug 2019
Results posted
No
Data monitoring committee
No
Individual data sharing
No

Publications

  • Guralnik JM, Simonsick EM, Ferrucci L, Glynn RJ, Berkman LF, Blazer DG, Scherr PA, Wallace RB. A short physical performance battery assessing lower extremity function: association with self-reported disability and prediction of mortality and nursing home admission. J Gerontol. 1994 Mar;49(2):M85-94. doi: 10.1093/geronj/49.2.m85.

    PubMed 8126356
  • Freiberger E, de Vreede P, Schoene D, Rydwik E, Mueller V, Frandin K, Hopman-Rock M. Performance-based physical function in older community-dwelling persons: a systematic review of instruments. Age Ageing. 2012 Nov;41(6):712-21. doi: 10.1093/ageing/afs099. Epub 2012 Aug 10.

    PubMed 22885845
  • Dodds RM, Syddall HE, Cooper R, Benzeval M, Deary IJ, Dennison EM, Der G, Gale CR, Inskip HM, Jagger C, Kirkwood TB, Lawlor DA, Robinson SM, Starr JM, Steptoe A, Tilling K, Kuh D, Cooper C, Sayer AA. Grip strength across the life course: normative data from twelve British studies. PLoS One. 2014 Dec 4;9(12):e113637. doi: 10.1371/journal.pone.0113637. eCollection 2014.

    PubMed 25474696
  • Kwon S, Perera S, Pahor M, Katula JA, King AC, Groessl EJ, Studenski SA. What is a meaningful change in physical performance? Findings from a clinical trial in older adults (the LIFE-P study). J Nutr Health Aging. 2009 Jun;13(6):538-44. doi: 10.1007/s12603-009-0104-z.

    PubMed 19536422
  • Nygard LAK, Mundal I, Dahl L, Saltyte Benth J, Rokstad AMM. Nutrition and physical performance in older people-effects of marine protein hydrolysates to prevent decline in physical performance: a randomised controlled trial protocol. BMJ Open. 2018 Oct 8;8(10):e023845. doi: 10.1136/bmjopen-2018-023845.

    PubMed 30297351

Questions about this trial

What is this clinical trial studying?

A study testing Marine Protein hydrolysate in people with Sarcopenia, run by Molde University College.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 28 Aug 2019. Status can change between updates, so confirm with the study contact before making plans.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Short Physical Performance Battery (SPPB) (time frame: 6 and 12 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02890290, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Aug 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in